Home > Back to Publisher > Report Information

Conference Documentation: Asthma & COPD (2010)

SMI Publishing, Ltd
April 21, 2010
SKU: SMI2770670

Abstract Table of Contents Related Reports

Products developed to treat the symptoms of Asthma and COPD provide one of the highest sources of revenue for the pharmaceutical industry. SMi’s 6th annual Asthma & COPD conference will present attendees with an exceptional line-up of speakers and an unrivalled forum for discussion and debate.

There will be an opportunity to hear about new research involving the use of bronchodilators and kinase-inhibitors as well as antibody based biologics. Presentations will also cover topics such as new therapeutic targets in asthma and COPD and optimising respiratory clinical trial data.

DAY 1
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks: Peter Barnes, Head of Respiratory Medicine, Imperial College London.
9.10 KEYNOTE ADDRESS: NOVEL MECHANISMS AND NEW THERAPEUTIC TARGETS IN ASTHMA AND COPD; Discuss progress in understanding asthma and COPD; Similarities between COPD and severe asthma; Developing biomarkers to aid drug development; What are the unmet needs?; Peter Barnes, Head of Respiratory Medicine, Imperial College London.
9.50 IMPACT OF DRUG SUBSTANCE AND PRODUCT CHARACTERISTICS ON IN-VITRO PERFORMANCE: Parameters affecting in-vitro and in-vivo performance; Parameters affecting stability; How can these parameters be measured?; Monitoring and control of parameters during development; Frank Thielmann, PDU Manager, Novartis.
10.30 Morning Coffee
10.50 TARGETING INFLAMMATION IN COPD: Lung cell models; Corticosteroid Insensitivity; Novel Targets; Clinical Trial Data; Dave Singh, Medical Director, Medicines Evaluation Unit, University Hospital Of South Manchester NHS Foundation Trust.
11.30 NOVEL AND EMERGING BRONCHODILATORS: Role of bronchodilators in the treatment of asthma and COPD; The need for long- acting bronchodilators; Evidence from in vitro studies; Emerging trends; Alan Young, Associate Director and Principal Scientist, AstraZeneca.
12.10 Networking Lunch
1.10 ANTIBODY BASED BIOLOGICS FOR THE TREATMENT OF ASTHMA: Areas for antibody based biologics to make an impact in the clinic; Review of pre-clinical and clinical data; Patient stratification; Future directions for biologicals in asthma; Matthew Catley, Head of Respiratory Pharmacology, UCB.
1.50 DEVELOPING THE PRE-CLINICAL PLATFORM OF EVIDENCE FOR COPD: Potential preclinical experiments; Outcomes and biomarkers; Link to human disease; Closing the translational loop; Thomas Eichholtz, Director of Discovery Medicine, AstraZeneca.
2.30 Afternoon Tea
2.50 EARLY PHARMACEUTICAL DEVELOPMENT: MAXIMISING PORTFOLIO DYNAMICS IN ASTHMA AND COPD: Understanding diversity of portfolio in early phase and CMC implications; Oral and inhalation key triggers for pharmaceutical development from lead optimisation to FIM/proof of principles; Candidate drug selection, ability to develop and risk management,; Example of properties evaluation from small molecules to oligonucleotides; Julien Giovanni, Team Manager Early Development, AstraZeneca.
3.30 PHASE 2 PROOF OF CONCEPT STUDIES FOR ASTHMA : WHAT ARE THE OPTIONS?: Bronchoprovocation and other challenges/mechanistic type studies; Clinical asthma POC studies; Which design is best? Strategic, logistical and sample size considerations; Michael Hodges, Chief Medical Officer, Altair Therapeutics.
4.50 Chairman’s Closing Remarks and Close of Day One
DAY 2
8.30 Re-registration & Coffee
9.00 Chairman's Opening Remarks: Peter Howarth, Reader in Medicine and Head of Clinical Translational Research, University Of Southampton School Of Medicine.
9.10 EMERGING AREAS IN AIRWAYS DISEASE: Respiratory microbiome; Biomechanical forces; Structural influences; Small airways; Peter Howarth, Reader in Medicine and Head of Clinical Translational Research, University Of Southampton School Of Medicine.
9.50 HUMAN IN VITRO MODELS AS TRANSLATIONAL RESEARCH TOOLS: The need to improve the ability of preclinical models to predict clinical outcome; Focus on models of mechanisms relevant to asthma and COPD; Examples of use of models for both target identification and target validation; Sourcing tissue and cells from subjects with lung diseases; Phillip Monk, Chief Scientific Officer, Synairgen.
10.30 Morning Coffee
11.00 LESSONS LEARNED IN CENTRALISED SPIROMETRY: Over reading systems the plus and minuses; Identifying abnormalities and their cause; Catching errors before they become issues; Case studies; Aleck Harrison, Consultant Clinical Scientist, AJH Partners.; Grant Sowman, Pulmonary Function Testing Specialist, Vitalograph.
11.40 PUTTING PHOSPHORYLATION IN THE FRAME: KINASES AS TARGETS FOR NEW THERAPIES: Signalling roles of protein and lipid kinases; Identification of kinase isoforms; Kinases as potential drug targets; Kinase inhibition as an approach to suppression of airway inflammation and remodelling; Gordon Dent , Senior Lecturer in Pharmacology, School of Medicine, Keele University.
12.20 Networking Lunch
1.30 OLIGONUCLEOTIDES: NEW THERAPEUTIC APPROACHES FOR ASTHMA AND COPD: Overview of the therapeutic class; Developments in targeting lung disease; Pre-clinical development : challenges and attributes; Emerging clinical data and product profiles; Mark Parry-Billings, Chief Executive Officer, Topigen Pharmaceuticals.
2.10 DOSING AND TARGETING STRATEGIES FOR PULMONARY CLINICAL TRIALS: Parameters influencing lung dose of inhaled drugs; Options to improve consistency in lung dose; Potential to improve quality of trial outcomes by controlled inhalation; Regulatory and commercial aspects of device selection during different development stages; Thomas Hofmann, Chief Medical Officer, Activaero.
2.50 DNAZYM TECHNOLOGY FOR ASTHMA TREATMENT: DNAzyme technology; Possible targets suitable for DNAzym approach; Off-target effects; Preclinical considerations; Harald Renz, Professor and Chairman, Department of Clinical Chemistry and Molecular Diagnostics - Central Laboratory, University Of Marburg.
3.30 Close of Conference and Afternoon Tea

Conference Documentation: Asthma & COPD (2010)

Share this report

Other tasks

Research Assistance

Related Markets

Asthma Reports

Free Alert Me service